TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily pill Juvmo, also known as tavapadon during clinical trials, on Sept. 25, 2026, for motor symptoms of Parkinson’s disease. It can be used alone in early Parkinson’s or added to existing medication in later stages; AbbVie expects U.S. availability in October. The 26-week trials reported symptom improvements, but the available evidence does not establish whether the drug reduces the risk of impulse control problems over time.
The U.S. Food and Drug Administration approved AbbVie’s once-daily pill Juvmo on Sept. 25 to treat motor symptoms of Parkinson’s disease. The drug, called tavapadon during clinical trials, is approved for use by itself in early Parkinson’s and alongside existing medication in later stages, giving clinicians another treatment option as they manage symptoms and medication effects.
AbbVie’s approval was supported by three randomized, placebo-controlled Phase 3 trials involving more than 1,300 participants. Each trial lasted 26 weeks. Two tested Juvmo as a standalone treatment and reported motor-symptom improvements described by the source report as noticeable and meaningful. Reported side effects in those trials were mild to moderate and included nausea and headache.
The third trial tested Juvmo as an add-on to existing Parkinson’s medication. It found that the drug helped extend “on time,” when medication is working, and reduce “off time,” when its effects wear off. These are trial findings reported by Being Patient; the source material does not provide numerical effect sizes or detailed comparisons between treatment groups.
Juvmo works by activating the D1 and D5 dopamine receptors. Many existing dopamine agonists act on D2 and D3 receptors. The different receptor targets may offer another approach to treating symptoms, but the source material does not establish that Juvmo avoids side effects associated with other Parkinson’s treatments.
A Once-Daily Option for Symptoms
Parkinson’s can cause tremors, rigidity, slowed movement and posture problems. Treatments can help manage motor symptoms, but some require multiple doses each day and can cause side effects that affect daily life. The approval adds a once-daily option for people with early disease and a possible add-on for people whose existing treatment wears off.
That dosing schedule and the option to use the pill at different stages may matter to patients and clinicians weighing how to manage symptoms. However, the approval does not mean the drug is suitable for every person with Parkinson’s, nor does it establish that it will reduce side effects for all patients. Treatment choices depend on individual circumstances and should be discussed with a qualified health professional.
Being Patient reports that more than one million people in the United States live with Parkinson’s. The article also describes side effects, including dyskinesia and impulse control disorders, as reasons some people discontinue medication. Juvmo’s trial results offer a new option to consider, while questions about longer-term effects remain.
How Juvmo Differs From Other Drugs
Parkinson’s disease involves the loss of neurons that produce dopamine, a neurotransmitter involved in movement. As dopamine-producing neurons die off, motor symptoms can develop. Dopamine agonists are medicines that mimic dopamine’s effects by activating receptors in the brain’s dopamine pathways.
According to Being Patient, many existing dopamine agonists target D2 and D3 receptors, while Juvmo activates D1 and D5 receptors. The difference in target receptors is the basis for the drug’s distinct approach. It does not, by itself, establish a lower risk of any particular side effect; that requires evidence from clinical use and further study.
The FDA approved Juvmo for two treatment settings: standalone use in early Parkinson’s and add-on use in later stages. The approval follows three 26-week trials. AbbVie expects the drug to be available in the United States in October 2026, according to the report.
““It’s not a huge game-changer, but definitely a nice additional tool to have.””
— Dr. Bryan Ho, neurologist and director of the Movement Disorders Program at Tufts Medical Center, speaking previously to Being Patient
Longer-Term Effects Remain Unknown
The trials lasted 26 weeks, and the source report says they were not long enough to determine whether Juvmo reduces the risk of impulse control problems. The report describes impulse control disorders, such as problematic gambling, as a concern with some Parkinson’s medications. It does not provide evidence that Juvmo prevents those problems.
The source material also gives no numerical estimates for symptom changes, the extension of on time, or the reduction in off time. It does not detail how trial participants compared with one another on specific outcomes or how results varied across patient groups. Those details would help readers judge the size and range of the reported benefits.
Reported nausea and headache were described as mild to moderate in the standalone trials, but the supplied report does not give a full safety profile or long-term follow-up findings. How the medicine performs in broader clinical use, and which patients are most likely to benefit, remain unclear from the available information.
U.S. Availability Expected in October
AbbVie expects Juvmo to become available in the United States in October 2026, according to Being Patient. The report does not give a specific launch date, pricing information, or details about insurance coverage. Patients and clinicians will have to check with the company, pharmacies, and insurers for those practical details as availability approaches.
After launch, clinicians and patients can weigh the approved uses, reported trial findings, potential side effects, and individual treatment needs when discussing whether the drug is appropriate. Longer-term clinical experience may also add information about tolerability and outcomes beyond the 26-week trials, including the unresolved question about impulse control problems.
Key Questions
What did the FDA approve?
The FDA approved AbbVie’s Juvmo, called tavapadon during clinical trials, to treat Parkinson’s motor symptoms. It is approved as a standalone treatment in early Parkinson’s and as an add-on in later stages.
When is Juvmo expected to be available?
AbbVie expects U.S. availability in October 2026. The source report does not name a specific date.
How is Juvmo different from many existing dopamine agonists?
According to Being Patient, Juvmo activates D1 and D5 dopamine receptors, while many existing dopamine agonists target D2 and D3 receptors.
What did the clinical trials find?
Three 26-week Phase 3 trials involving more than 1,300 participants supported the approval. The standalone trials reported motor-symptom improvements; the add-on trial reported longer on time and less off time. The source report does not provide numerical effect sizes.
Is it known whether Juvmo reduces impulse control problems?
No. The source report says the trials were not long enough to determine whether the treatment reduces the risk of impulse control problems.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
